[{"id":"46d40afb-f92b-4877-a910-259a8f39fc7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02735798","created_at":"2021-01-18T13:23:49.662Z","updated_at":"2024-07-02T16:37:22.825Z","phase":"Phase 1","brief_title":"64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets","source_id_and_acronym":"NCT02735798","lead_sponsor":"Pamela Munster","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • doxorubicin hydrochloride • MM-302"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2017-05-04"}]